Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Caldure Plus is a multi-ingredient nutritional supplement developed and marketed by Tabq Therapeutics. It is formulated to support bone mineral density and address nutritional deficiencies. The product typically combines calcium citrate, a form of calcium with high bioavailability, with cholecalciferol (vitamin D3), which is essential for the intestinal absorption of calcium and phosphate. Additionally, it includes magnesium and zinc, which serve as vital cofactors in bone metabolism and enzymatic processes. Caldure Plus is primarily indicated for the prevention and treatment of bone-related disorders such as osteoporosis, osteomalacia, and rickets, as well as for meeting increased calcium demands during pregnancy, lactation, and aging.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Caldure Plus.